Amarin Corp Plcuk (AMRN) Non-Current Debt (2010 - 2019)
Amarin Corp Plcuk (AMRN) reported Non-Current Debt of $8.9 million for Q3 2019, down 69.55% year-over-year from $29.2 million in Q3 2018, and down 61.74% quarter-over-quarter from $23.2 million in Q2 2019.
Amarin Corp Plcuk (AMRN) Non-Current Debt (2010 - 2019) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 10 years of Non-Current Debt data on file, last reported at $8.9 million in Q3 2019.
- Non-Current Debt for Q3 2019 came in at $8.9 million, down 69.55% year-over-year; the trailing twelve-month figure through Sep 2019 was $8.9 million (down 69.55% YoY), and the FY2018 annual result was $46.1 million, up 59.04% from the prior year.
- Non-Current Debt fell to $8.9 million in Q3 2019 per AMRN's latest filing, from $23.2 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $136.7 million in Q4 2015 and troughed at $8.9 million in Q3 2019.
- A 5-year average of $64.7 million and a median of $62.7 million in 2017 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2018 and 2019: Non-Current Debt jumped 59.04% in 2018, then tumbled 69.55% in 2019.
- A 5-year view of Non-Current Debt shows it stood at $136.7 million in 2015, then slumped by 37.72% to $85.2 million in 2016, then plunged by 65.95% to $29.0 million in 2017, then jumped by 59.04% to $46.1 million in 2018, then plunged by 80.75% to $8.9 million in 2019.
- Business Quant data shows AMRN's Non-Current Debt at $8.9 million in Q3 2019, $23.2 million in Q2 2019, and $35.3 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -18.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 39.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 37.53 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 42.15 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 8.88 Mn |
| Sep 30, 2019 | 8.88 Mn |
| Jun 30, 2019 | 23.20 Mn |
| Jun 30, 2019 | 23.20 Mn |
| Mar 31, 2019 | 35.34 Mn |
| Mar 31, 2019 | 35.34 Mn |
| Dec 31, 2018 | 46.11 Mn |
| Dec 31, 2018 | 46.11 Mn |
| Sep 30, 2018 | 29.16 Mn |
| Sep 30, 2018 | 29.16 Mn |
| Jun 30, 2018 | 29.10 Mn |
| Jun 30, 2018 | 29.10 Mn |
| Mar 31, 2018 | 29.05 Mn |
| Mar 31, 2018 | 29.05 Mn |
| Dec 31, 2017 | 28.99 Mn |
| Dec 31, 2017 | 28.99 Mn |
| Sep 30, 2017 | 28.94 Mn |
| Sep 30, 2017 | 28.94 Mn |
| Jun 30, 2017 | 79.28 Mn |
| Jun 30, 2017 | 79.28 Mn |